(Q35350975)

7 August 2017

Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea (English)

1 reference

7 August 2017

0 references

1 reference

1 reference

9

A R Zinsmeister

1 reference

7 August 2017

8

H C Pitot

1 reference

7 August 2017

S B Saslow

1

1 reference

7 August 2017

J S Scolapio

2

1 reference

7 August 2017

M Camilleri

3

1 reference

7 August 2017

L A Forstrom

4

1 reference

7 August 2017

G M Thomforde

5

1 reference

7 August 2017

D D Burton

6

1 reference

7 August 2017

J Rubin

7

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 May 1998

1 reference

7 August 2017

1 reference

7 August 2017

42

1 reference

7 August 2017

5

1 reference

7 August 2017

628-634

1 reference

The management of patients with advanced carcinoid tumors and islet cell carcinomas

7 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727117

The effects of the 5-hydroxytryptamine (5HT3) receptor antagonist ICS 205-930 in the carcinoid syndrome

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727117

Human gastric emptying and colonic filling of solids characterized by a new method

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727117

Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727117

Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727117

GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727117

Towards a less costly but accurate test of gastric emptying and small bowel transit

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727117

A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727117

Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727117

Ondansetron in carcinoid syndrome

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727117

Gastrointestinal and metabolic function in patients with the carcinoid syndrome

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727117

Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727117

Serotonergic mediation of postprandial colonic tonic and phasic responses in humans

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727117

A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727117

Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727117

Effect of a new oral somatostatin analog (SDZ CO 611) on gastric emptying, mouth to cecum transit time, and pancreatic and gut hormone release in normal male subjects.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727117

Effects of 5-HT3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727117

Jejunal fluid and electrolyte secretion in carcinoid syndrome

26 September 2018

1 reference

12 December 2020

[Long acting sandostatine (sandostatine LAR) in the treatment of acromegaly]

1 reference

12 December 2020

Elevated concentrations of substance p and 5-HT in plasma in patients with carcinoid tumors

1 reference

12 December 2020

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue

1 reference

12 December 2020

Transit of solids through the human colon: regional quantification in the unprepared bowel

1 reference

12 December 2020

Towards a relatively inexpensive, noninvasive, accurate test for colonic motility disorders

1 reference

12 December 2020

Ondansetron in carcinoid syndrome

1 reference

12 December 2020

Alosetron does not affect the visceral perception of gastric distension in healthy subjects

1 reference

12 December 2020

Treatment of diarrhea in carcinoid syndrome with ondansetron, tropisetron, and clonidine

1 reference

12 December 2020

Identifiers

DOI

10.1136/GUT.42.5.628

1 reference

7 August 2017

1 reference

7 August 2017

1 reference